Total
0
Shares
Sona Nanotech Inc., - CEO, Darren Rowles
CEO, Darren Rowles
Source: Inkwood Research
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Sona Nanotech (SONA) is launching a new research program to explore its proprietary gold nanorod technology
  • The company will collaborate with Dr. Warren Chan from the University of Toronto to conducts this research
  • Sona will use the data from this and future programs to identify the most promising medical applications for its technology
  • Sona Nanotech is a nanotechnology life sciences firm
  • Shares in Sona Nanotech Inc. (SONA) are up 3.37 per cent, trading at $0.46 per share

Sona Nanotech (SONA) is launching a new research program to explore its proprietary gold nanorod technology.

The company will collaborate with Dr. Warren Chan from the University of Toronto to conduct this research.

Dr. Chan serves as Canada Research Chair in Nanobioengineering and Director of the Institute of Biomedical Engineering at the University of Toronto.

Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.

Sona’s research collaborations will leverage the expertise and scientific leadership of a group of third-party, respected scientists and entrepreneurs to work with Sona’s team.

Under this research agreement, Sona will consult with Dr. Chan on the design and execution of studies that will determine the biocompatibility of the proprietary technology.

“The biocompatibility of nanomaterials will be an important component to the unlocking of new, potentially life-saving, medical nanotechnology applications,” said Dr. Chan, “and so our study will explore Sona Nanotech’s gold nanorods as a safe, non-toxic material for use ‘in-vivo’.”

This research program will provide a foundation for future programs, which Sona will use to identify the most promising medical applications for its technology.

Darren Rowles, president and Chief Scientific Officer of Sona, commented on the research collaboration.

“We are delighted to be working with Dr. Chan, one of the most important nanotechnology scientists in the world, and we are excited to explore with him the unique attributes and benefits our technology may bring to enabling new, important biomedical applications.”

Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles.

Shares in Sona Nanotech Inc. (SONA) are up 3.37 per cent, trading at $0.46 per share as of 3:53 pm ET.

More From The Market Herald
Theratechnologies - CEO, Paul Lévesque.

" Theratechnologies (TSX:TH) receives 2021 ADRIQ Innovation Award

Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category.
Constellation Software - President, Mark Leonard.

" Constellation Software (TSX:CSU) announces venture capital fund

Constellation Software (CSU) will form a C$200M venture capital fund focused on vertical market software.

" Robin van Poelje named as Chief Executive Officer of Topicus.com (TSXV:TOI)

Topicus.com has appointed Robin van Poelje as Chief Executive Officer, effective immediately.

" Elixxer Ltd. (TSXV:ELXR) welcomes new director

Elixxer (ELXR) is pleased to welcome Mr. Jeremy Green to the corporation’s board of directors.